300 North Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

300 North Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,609	Closed	-$736K	–	93
2015 Q1	$736K	Buy	2,609 +14	+0.5%	+$3.03K	0.16%	98
2014 Q4	$405K	Buy	2,595 +7	+0.3%	+$1.29K	0.09%	101
2014 Q3	$612K	Hold	2,588	–	–	0.16%	95
2014 Q2	$612K	Hold	2,588	–	–	0.15%	86
2014 Q1	$854K	Buy	+2,588	New	+$873K	0.22%	83

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

300 North Capital's ICPT Position: Q2 2015 in Review

300 North Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2015, closing a stake of 2,609 shares — an estimated $736K sold.

300 North Capital first reported a position in ICPT in Q1 2014 and held it in 5 quarters. The position peaked at $854K in Q1 2014. 191 funds tracked by Wall St. Rank hold ICPT as of Q2 2015.

300 North Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
300 North Capital sold 2,609 Intercept Pharmaceuticals, Inc. shares in Q2 2015, an estimated $736K.
300 North Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
300 North Capital's Intercept Pharmaceuticals, Inc. position peaked at $854K in Q1 2014.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.